CRISPR/Cas9 License Agreement for ERS Genomics and CIEA
PR95301
DUBLIN, Apr. 7, 2022, /PRNewswire=KYODO JBN/--
ERS Genomics Limited (ERS) is pleased to announce a license agreement with
Central Institute for Experimental Animals (CIEA) in Japan. This is a
non-exclusive licensing agreement granting CIEA access to the ERS CRISPR/Cas9
patent portfolio.
ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for
gene-editing, provides access to the foundational CRISPR/Cas9 intellectual
property. Eighty-nine patents are held in over eighty countries.
CIEA is a private and independent non-profit institute, founded in 1952, with
the aim of contributing to medical care and medical science based on the
ethical use of animals in modelling of diseases and treatments.
CEO, Eric Rhodes had the following statement: ‘“CRISPR/Cas9 is a powerful
genome engineering tool that has revolutionized the arena of biotechnology. At
ERS, we are committed to making our technology accessible and available. We are
pleased to be able to support CIEA, a company recognized worldwide for their
excellence in the development of novel animal models for research.”
CEO of CIEA, Ryuta Nomura had the following to say about how CRISPR/Cas9
technology benefits CIEA’s contributions to healthcare globally: “The progress
and evolution of gene-editing technology has been remarkable. CRISPR/Cas9 has
actually changed not only the methodology but also the way of thinking in the
field of medicine and biology.”
Financial details of the agreement are not disclosed.
About ERS Genomics
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company
was formed to provide broad access to the foundational CRISPR/Cas9 intellectual
property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are
available for research and sale of products and services across multiple fields
including: research tools, kits, reagents; discovery of novel targets for
therapeutic intervention; cell lines for discovery and screening of novel drug
candidates; GMP production of healthcare products; companion animal and
livestock health; production of industrial materials such as enzymes, biofuels
and chemicals; and synthetic biology.
For additional information, please visit: www.ersgenomics.com
About Central Institute for Experimental Animals:
Central Institute for Experimental Animals is a private and independent
non-profit institute, founded in Japan in 1952 with the aim of contributing to
medical care and medical science based on animal experiments. CIEA is renowned
for the research, development and commercialization of the world's most
advanced laboratory animals and germ-free animal-related technologies that
provide technologies such as monitoring tests, pathology tests, genetic
modification, developmental engineering, and image analysis. CIEA collaborates
and cooperates with universities and research institutions in Japan and other
countries, international public organizations such as WHO, NIH, FDA, and NIBSC,
and other business enterprises.
For additional information, please visit: www.ciea.or.jp/en/
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo
Corporation, serves as the exclusive agent for ERS Genomics in Japan.
Photo: https://mma.prnewswire.com/media/1778872/ERS_Genomics_Eric_Rhodes.jpg
Caption: Eric Rhodes, CEO, ERS Genomics
Logo: https://mma.prnewswire.com/media/1756881/ERS_Genomics_Logo.jpg
Photo: https://mma.prnewswire.com/media/1778870/Ryuta_Nomura.jpg
Caption: Ryuta Nomura, CEO, CIEA
Logo: https://mma.prnewswire.com/media/1778871/CIEA_Logo.jpg
Source: ERS Genomics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。